451 related articles for article (PubMed ID: 23798998)
1. Distinct microRNA expression profile in prostate cancer patients with early clinical failure and the impact of let-7 as prognostic marker in high-risk prostate cancer.
Schubert M; Spahn M; Kneitz S; Scholz CJ; Joniau S; Stroebel P; Riedmiller H; Kneitz B
PLoS One; 2013; 8(6):e65064. PubMed ID: 23798998
[TBL] [Abstract][Full Text] [Related]
2. A TMEFF2-regulated cell cycle derived gene signature is prognostic of recurrence risk in prostate cancer.
Georgescu C; Corbin JM; Thibivilliers S; Webb ZD; Zhao YD; Koster J; Fung KM; Asch AS; Wren JD; Ruiz-Echevarría MJ
BMC Cancer; 2019 May; 19(1):423. PubMed ID: 31060542
[TBL] [Abstract][Full Text] [Related]
3. The association of let-7c, miR-21, miR-145, miR-182, and miR-221 with clinicopathologic parameters of prostate cancer in patients diagnosed with low-risk disease.
Kurul NO; Ates F; Yilmaz I; Narli G; Yesildal C; Senkul T
Prostate; 2019 Jul; 79(10):1125-1132. PubMed ID: 31045265
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
Pashaei E; Pashaei E; Ahmady M; Ozen M; Aydin N
PLoS One; 2017; 12(6):e0179543. PubMed ID: 28651018
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA let-7c is downregulated in prostate cancer and suppresses prostate cancer growth.
Nadiminty N; Tummala R; Lou W; Zhu Y; Shi XB; Zou JX; Chen H; Zhang J; Chen X; Luo J; deVere White RW; Kung HJ; Evans CP; Gao AC
PLoS One; 2012; 7(3):e32832. PubMed ID: 22479342
[TBL] [Abstract][Full Text] [Related]
6. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
7. Meta-analysis of transcriptome reveals let-7b as an unfavorable prognostic biomarker and predicts molecular and clinical subclasses in high-grade serous ovarian carcinoma.
Tang Z; Ow GS; Thiery JP; Ivshina AV; Kuznetsov VA
Int J Cancer; 2014 Jan; 134(2):306-18. PubMed ID: 23825028
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of miRNA host gene promoter methylation in prostate cancer.
Daniunaite K; Dubikaityte M; Gibas P; Bakavicius A; Rimantas Lazutka J; Ulys A; Jankevicius F; Jarmalaite S
Hum Mol Genet; 2017 Jul; 26(13):2451-2461. PubMed ID: 28398479
[TBL] [Abstract][Full Text] [Related]
9. Novel diagnostic and prognostic classifiers for prostate cancer identified by genome-wide microRNA profiling.
Kristensen H; Thomsen AR; Haldrup C; Dyrskjøt L; Høyer S; Borre M; Mouritzen P; Ørntoft TF; Sørensen KD
Oncotarget; 2016 May; 7(21):30760-71. PubMed ID: 27120795
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs as prognostic markers in prostate cancer.
Suer I; Guzel E; Karatas OF; Creighton CJ; Ittmann M; Ozen M
Prostate; 2019 Feb; 79(3):265-271. PubMed ID: 30345533
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
12. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
Schmidt L; Fredsøe J; Kristensen H; Strand SH; Rasmussen A; Høyer S; Borre M; Mouritzen P; Ørntoft T; Sørensen KD
Ann Oncol; 2018 Sep; 29(9):2003-2009. PubMed ID: 30010760
[TBL] [Abstract][Full Text] [Related]
13. Salivary microRNA miR-let-7a-5p and miR-3928 could be used as potential diagnostic bio-markers for head and neck squamous cell carcinoma.
Fadhil RS; Wei MQ; Nikolarakos D; Good D; Nair RG
PLoS One; 2020; 15(3):e0221779. PubMed ID: 32208417
[TBL] [Abstract][Full Text] [Related]
14. HMGA1 and HMGA2 expression and comparative analyses of HMGA2, Lin28 and let-7 miRNAs in oral squamous cell carcinoma.
Sterenczak KA; Eckardt A; Kampmann A; Willenbrock S; Eberle N; Länger F; Kleinschmidt S; Hewicker-Trautwein M; Kreipe H; Nolte I; Murua Escobar H; Gellrich NC
BMC Cancer; 2014 Sep; 14():694. PubMed ID: 25245141
[TBL] [Abstract][Full Text] [Related]
15. Identification of microRNA signature and potential pathway targets in prostate cancer.
Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
[TBL] [Abstract][Full Text] [Related]
16. Identification of miR-30d as a novel prognostic maker of prostate cancer.
Kobayashi N; Uemura H; Nagahama K; Okudela K; Furuya M; Ino Y; Ito Y; Hirano H; Inayama Y; Aoki I; Nagashima Y; Kubota Y; Ishiguro H
Oncotarget; 2012 Nov; 3(11):1455-71. PubMed ID: 23231923
[TBL] [Abstract][Full Text] [Related]
17.
de Almeida BC; Dos Anjos LG; Uno M; Cunha IWD; Soares FA; Baiocchi G; Baracat EC; Carvalho KC
Cells; 2019 Nov; 8(11):. PubMed ID: 31744257
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of ARID4A and ARID4B promote tumor progression and directly regulated by microRNA-30d in patient with prostate cancer.
Liang YK; Han ZD; Lu JM; Liu ZZ; Zhuo YJ; Zhu XJ; Chen JX; Ye JH; Liang YX; He HC; Zhong WD
J Cell Biochem; 2018 Sep; 119(9):7245-7255. PubMed ID: 29797600
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive study of gene and microRNA expression related to epithelial-mesenchymal transition in prostate cancer.
Katz B; Reis ST; Viana NI; Morais DR; Moura CM; Dip N; Silva IA; Iscaife A; Srougi M; Leite KR
PLoS One; 2014; 9(11):e113700. PubMed ID: 25409297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
